Assembly Biosciences (NASDAQ:ASMB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a strong-buy rating in a research note released on Sunday.

Several other research firms also recently issued reports on ASMB. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Assembly Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $41.75.

Assembly Biosciences Stock Up 4.2%

Shares of NASDAQ:ASMB opened at $27.75 on Friday. The firm has a market cap of $440.20 million, a P/E ratio of -37.50 and a beta of 1.11. Assembly Biosciences has a 12 month low of $7.75 and a 12 month high of $39.71. The company’s 50-day moving average price is $27.89 and its two-hundred day moving average price is $29.91.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The company had revenue of $42.47 million for the quarter, compared to analyst estimates of $7.42 million. As a group, equities analysts predict that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

Institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC increased its holdings in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Assembly Biosciences by 6.9% during the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 3,312 shares during the last quarter. Ellsworth Advisors LLC bought a new position in Assembly Biosciences during the third quarter worth about $852,000. Vanguard Group Inc. grew its position in shares of Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after buying an additional 248,287 shares during the period. Finally, Patient Square Capital LP acquired a new position in shares of Assembly Biosciences during the 3rd quarter worth about $3,461,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.